Nemus Bioscience had a productive year, advancing multiple drug candidates in oncology supportive care, ophthalmology, and anti-infectives. Key achievements included licensing CBD derivatives from the University of Mississippi, completing preclinical studies, and establishing partnerships for drug development and manufacturing. Looking forward, Nemus aims to maintain financing, advance formulations, form strategic partnerships, qualify for grants, and increase awareness to support its pipeline of cannabinoid-based therapies. The main challenges will be securing adequate capital and establishing partnerships to fund development in a non-dilutive manner.

1. Shareholder Presentation
July 12, 2016
NEMUS Bioscience
OTCQB: NMUS

2. 2
Forward Looking Statement
This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. All of the statements in this presentation, whether written or oral, that refer to expected or anticipated future
actions and results of NEMUS Bioscience, Inc. (NEMUS) are forward-looking statements. These forward-looking statements reflect the
beliefs and expectations of the management of NEMUS as of the date of this presentation. NEMUS cannot give any assurance that such
forward-looking statements will prove to be correct. The reader is cautioned not to place undue reliance on these forward-looking
statements.
The information provided in this presentation does not identify or include any risk or exposures, of NEMUS that would materially adversely
affect the performance or risk of the company. For a description of the risks and uncertainties related to the business of NEMUS, see our
Annual Report on Form 10-K filed with the Securities and Exchange Commission and our subsequent periodic reports filed with the
Securities and Exchange Commission.
All information contained in this presentation is provided as of the date of the presentation and is subject to change without notice. Neither
NEMUS, nor any other person undertakes any obligation to update or revise publicly any of the forward-looking statements set out herein,
whether as a result of new information, future events or otherwise, except as required by law. This presentation does not convey an offer of
any type and is not intended to be, and should not be construed as, an offer to sell, or the solicitation of an offer to buy, any securities of
NEMUS.

3. The Year in Review: Nemus
• Company Achievements:
• Enhanced relationship with the University of Mississippi by completing in-licensing of CBD derivatives,
developing potential anti-MRSA therapies, creating intellectual property for multiple cannabinoid derivatives
as well as Dr. Murphy participating as a visiting faculty member at the University
• The Company remained fully compliant with financial reporting responsibilities as a publicly traded entity
• Completed a series B $5 million financing in August, 2015
• Added internationally recognized experts as scientific advisors to the company in the area of ophthalmology
(Dr. Robert Weinreb) and palliative care (Dr. Donald Abrams)
• Partnered with premier drug development organizations to advance our candidate products:
Ø Albany Molecular Research, Inc.; prominent drug product manufacturer for cannabinoids
Ø Catalent Pharma Solutions; formulation consultants and manufacturers
Ø Atheln, Inc.; drug development and CMC consultants
Ø RRD International; regulatory consultants with special expertise in 505(b)(2) regulatory pathway
• Conducted strategic pipeline review and established three therapeutic silos for product development based
on unique molecular candidates developed by the University of Mississippi
• Palliative Care (CINV AND CIPN)
• Ophthalmology (Glaucoma)
• Anti-infectives (MRSA)

4. The Year In Review: Developmental Milestones
• Chemotherapy-induced nausea/vomiting (CINV): NB1222 (THC prodrug)
• Drug synthesis pathway elucidated for THC-val-HS
• Drug production scale-up begun
• Initial drug product for commercial scalability produced
• Suppository formulation has been initiated
• Regulatory dossier preparation for pre-IND meeting initiated
• Chemotherapy-induced peripheral neuropathy (CIPN): NB2111 (CBD derivative)
• CBD derivatives patent filed
• Murine tactile allodynia experiments performed exhibiting comparable analgesia between CBD
derivative versus high-dose morphine
• CBD derivative exhibits capability to traverse physiological compartments widening scope of overall
therapeutic indications, including the CNS and immune system
• Glaucoma: NB1111 (THC prodrug)
• Multiple rabbit glaucoma model studies completed
• Findings consistently show IOP decline on average of 45%
• NB1111 in solid lipid nanoparticle able to enter multiple compartments in the eye, including the
posterior compartment housing the optic nerve
• Japanese patent granted for NB1111/NB1222 (see CINV)

5. The Year In Review: Developmental Milestones
• Methicillin-resistant Staphylococcus aureus (MRSA): multiple cannabinoids
• Identification of multiple cannabinoid molecules with activity against multiple species of MRSA
• Identification and validation of synergistic killing activity by strategic cannabinoid combinations
• Patent developed for the use of cannabinoid molecules against gram positive organisms, including MRSA
• Initiated studies to elucidate the mechanism of action of cannabinoids against MRSA
• MRSA species studied included but not limited to: community-acquired, hospital-acquired, and mupirocin-
resistant strains
• Patents issued or filed:
• Multiple prodrug formulations of THC, including NB1111 and NB2111, issued in the United States and
Japan; European Union and rest-of-world (ROW) pending
• Multiple prodrug and analogue formulations of CBD filed globally
• Multiple cannabinoids alone or in combination, for the management of gram positive infections, including
MRSA
• Competitive innovation in product synthesis: biosynthetic production of cannabinoids
• Entered into Letter of Intent with Teewinot Life Sciences, the only entity with global patents for the
biosynthetic production of cannabinoids using yeast or bacteria fermentation
• Agreement to cover the biosynthetic manufacturing of all proprietary Nemus cannabinoids
• Agreement with Teewinot is in conjunction with Nemus API manufacturer, AMRI
• Could result in significant savings on cost-of-manufacturing and cost-of-goods sold

6. Nemus goals for 2016 - 2017
• Maintain adequate financing to allow timely product development and allow the
company to qualify to up-list to either the NASDAQ or NYSE
• Develop formulations conducive to the various routes of administration offered by the
molecular engineering associated with cannabinoid prodrugs
• Enter into strategic business development agreements related to our current product
silos that can help expedite development leading to timely commercialization
• Work in conjunction with the University of Mississippi to qualify for government and/
or foundation grants leading to non-dilutional funding of the product pipeline
• Enter into human testing of NB1111 and NB2111 by end of Q1’17
• Complete MRSA anti-infective testing by the end of Q3’16 and create a dossier for the
sale of the antibiotic platform against gram positive organisms by Q2’17
• Develop unique derivatives of other cannabinoids located in the cannabis plant
• Enhance the Nemus media profile so that the company is used as a comparator to
sector incumbents like GW Pharma and Insys
• Increase awareness in investment community about Nemus

7. The Year in Review: Future Challenges
• As an early stage biotechnology company, the main challenges Nemus faces going
forward include:
• Adequate capital to allow timely execution on the developmental timelines
leading to commercialization of our candidate drug products
• Successful formulation of cannabinoid drug candidates to achieve optimal
routes of administration that leverage Nemus’ prodrug and drug analogue
strategy
• The ability to form strategic partnerships with industry leaders in various
therapeutic indications that benefit Nemus as a cannabinoid-incubator;
allowing the company to bring newer cannabinoid target molecules forward
using non-dilutional funding from partnerships
• The ability of the company to leverage developmental success coupled to
strategic partnerships to qualify to up-list from the OTC to a larger exchange,
creating a more liquid trading environment for the stock